Is NBSE or SCHD a better dividend investment in 2026?

NBSE currently yields 529.10% with a 5% 5-year dividend growth rate. SCHD yields 3.44% with 13.05% growth. The better choice depends on your goal: NBSE offers higher current income.

What is the dividend yield difference between NBSE and SCHD?

NBSE has a forward dividend yield of 529.10% ($2.00/share annually). SCHD yields 3.44% ($1.06/share annually). The yield gap is 525.66 percentage points.

Home › Compare › NBSE vs SCHD

NBSE vs SCHD: Dividend Comparison 2026

NBSE yields 529.10% · SCHD yields 3.44%● Live data

vsPost on X →

After 10 years · $10,000 invested · DRIP enabled

🏆 NBSE wins by $95355.93M in total portfolio value

INVESTMENT

TIME HORIZON10 years

NBSE

● Live price

529.10%

Share price

$0.38

Annual div

$2.00

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$95355.96M

Annual income

$69,511,989,565.27

Full NBSE calculator →

SCHD

Schwab U.S. Dividend Equity ETF

● Live price

3.44%

Share price

$30.68

Annual div

$1.06

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$29.0K

Annual income

$422.61

Full SCHD calculator →

Portfolio growth — NBSE vs SCHD

📍 NBSE pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis Period	NBSE	SCHD
2008–2009 GFC	— No data	— No data
2020 Q1–Q2 COVID	— No data	— No data
2022 Q4 Rate Hike	— No data	— No data

Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.

📅

Dividend Calendar Overlap

Combined, NBSE + SCHD cover 0 of 12 months — good coverage

Jan

—

Feb

—

Mar

—

Apr

—

May

—

Jun

—

Jul

—

Aug

—

Sep

—

Oct

—

Nov

—

Dec

—

NBSE pays

SCHD pays

Both pay

Neither

💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

NBSE

Annual income on $10K today (after 15% tax)

$44,973.54/yr

After 10yr DRIP, annual income (after tax)

$59,085,191,130.48/yr

SCHD

Annual income on $10K today (after 15% tax)

$292.49/yr

After 10yr DRIP, annual income (after tax)

$359.22/yr

At 15% tax rate, NBSE beats the other by $59,085,190,771.26/year in after-tax income after 10 years on $10,000

⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of NBSE + SCHD for your $10,000?

NBSE: 50%SCHD: 50%

100% SCHD50/50100% NBSE

Portfolio after 10yr

$47678.00M

Annual income

$34,755,994,993.93/yr

Blended yield

72.90%

🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

NBSE buys

SCHD buys

No recent congressional trades found for NBSE or SCHD in the last 90 days.

STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →

MetricNBSESCHD

Forward yield	529.10% ✓	3.44%
Annual dividend / share	$2.00 ✓	$1.06
Payout ratio	50%	50%
1-year div growth	0%	0%
5-year div CAGR	0%	0%
Portfolio after 10y	$95355.96M ✓	$29.0K
Annual income after 10y	$69,511,989,565.27 ✓	$422.61
Total dividends collected	$93138.90M ✓	$3.9K
Payment frequency	quarterly	quarterly
Sector	Stock	ETF

Year-by-year: NBSE vs SCHD ($10,000, DRIP)

Year	NBSE Portfolio	NBSE Income/yr	SCHD Portfolio	SCHD Income/yr	Gap
1← crossover	$63,610	$52,910.05	$11,224	$344.10	+$52.4K → NBSE
2	$382,606	$314,543.11	$12,567	$354.98	+$370.0K → NBSE
3	$2,177,551	$1,768,162.86	$14,038	$365.30	+$2.16M → NBSE
4	$11,734,902	$9,404,922.59	$15,648	$375.06	+$11.72M → NBSE
5	$59,924,074	$47,367,729.01	$17,410	$384.27	+$59.91M → NBSE
6	$290,177,156	$226,058,396.40	$19,335	$392.95	+$290.16M → NBSE
7	$1,333,544,009	$1,023,054,452.33	$21,437	$401.10	+$1333.52M → NBSE
8	$5,820,882,501	$4,393,990,410.63	$23,733	$408.75	+$5820.86M → NBSE
9	$24,153,246,984	$17,924,902,708.82	$26,237	$415.91	+$24153.22M → NBSE
10	$95,355,963,839	$69,511,989,565.27	$28,968	$422.61	+$95355.93M → NBSE

NBSE vs SCHD: Complete Analysis 2026

NBSE — Stock

NeuBase Therapeutics, Inc., a pre-clinical-stage biopharmaceutical company, focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes. The company's proprietary modular peptide-nucleic acid antisense oligo (PATrOL) platform focuses on addressing Huntington's disease (HD) and myotonic dystrophy, as well as other genetic disorders, and cancer and oncology applications. Its lead programs include NT0100, a PATrOL enabled anti-gene for Huntington's disease; NT0200, a PATrOL enabled anti-gene for myotonic dystrophy type 1; NT0300, a PATrOL-enabled therapeutic treatment to target the mutated KRAS gene. NeuBase Therapeutics, Inc. is headquartered in Pittsburgh, Pennsylvania.

Full NBSE Calculator →

SCHD — ETF

The fund’s goal is to track as closely as possible, before fees and expenses, the total return of the Dow Jones U.S. Dividend 100 Index.

Full SCHD Calculator →

📬

Get this NBSE vs SCHD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

NBSE vs JEPI NBSE vs O NBSE vs KO NBSE vs MAIN NBSE vs VYM NBSE vs DGRO NBSE vs VIG NBSE vs HDV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.